Analysts predict that Miragen Therapeutics Inc (NASDAQ:MGEN) will report sales of $1.38 million for the current fiscal quarter, according to Zacks. Two analysts have provided estimates for Miragen Therapeutics’ earnings, with the lowest sales estimate coming in at $1.35 million and the highest estimate coming in at $1.40 million. Miragen Therapeutics posted sales of $4.78 million in the same quarter last year, which would indicate a negative year-over-year growth rate of 71.1%. The company is expected to issue its next quarterly earnings report on Wednesday, May 8th.

According to Zacks, analysts expect that Miragen Therapeutics will report full-year sales of $4.43 million for the current year, with estimates ranging from $2.00 million to $5.78 million. For the next financial year, analysts forecast that the company will report sales of $5.89 million, with estimates ranging from $5.78 million to $6.00 million. Zacks’ sales averages are a mean average based on a survey of sell-side research firms that that provide coverage for Miragen Therapeutics.

Miragen Therapeutics (NASDAQ:MGEN) last announced its quarterly earnings results on Wednesday, March 13th. The medical research company reported ($0.33) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.31) by ($0.02). Miragen Therapeutics had a negative net margin of 389.97% and a negative return on equity of 51.82%. The business had revenue of $0.48 million during the quarter, compared to the consensus estimate of $1.54 million.

A number of brokerages recently commented on MGEN. ValuEngine downgraded shares of Miragen Therapeutics from a “buy” rating to a “hold” rating in a report on Monday, April 1st. Zacks Investment Research downgraded shares of Miragen Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, March 22nd. Wedbush reaffirmed an “outperform” rating and issued a $24.00 price target (up previously from $22.00) on shares of Miragen Therapeutics in a report on Monday, March 18th. Robert W. Baird began coverage on shares of Miragen Therapeutics in a report on Friday, January 4th. They issued an “outperform” rating for the company. Finally, B. Riley began coverage on shares of Miragen Therapeutics in a report on Monday, December 31st. They issued a “buy” rating and a $18.50 price target for the company. Two investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company. Miragen Therapeutics has an average rating of “Buy” and a consensus price target of $16.19.

Shares of NASDAQ:MGEN traded up $0.19 during trading on Tuesday, reaching $2.92. The company’s stock had a trading volume of 113,491 shares, compared to its average volume of 212,583. The company has a current ratio of 9.71, a quick ratio of 9.71 and a debt-to-equity ratio of 0.16. Miragen Therapeutics has a 12 month low of $2.20 and a 12 month high of $7.94. The company has a market cap of $88.13 million, a price-to-earnings ratio of -2.65 and a beta of 1.21.

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Dimensional Fund Advisors LP lifted its stake in Miragen Therapeutics by 2.1% in the fourth quarter. Dimensional Fund Advisors LP now owns 216,866 shares of the medical research company’s stock worth $657,000 after purchasing an additional 4,404 shares during the last quarter. SG Americas Securities LLC lifted its stake in Miragen Therapeutics by 7.2% in the fourth quarter. SG Americas Securities LLC now owns 99,324 shares of the medical research company’s stock worth $301,000 after purchasing an additional 6,662 shares during the last quarter. Bank of America Corp DE lifted its stake in Miragen Therapeutics by 35.9% in the fourth quarter. Bank of America Corp DE now owns 33,116 shares of the medical research company’s stock worth $100,000 after purchasing an additional 8,756 shares during the last quarter. Rhumbline Advisers lifted its stake in Miragen Therapeutics by 51.4% in the fourth quarter. Rhumbline Advisers now owns 33,350 shares of the medical research company’s stock worth $101,000 after purchasing an additional 11,321 shares during the last quarter. Finally, Geode Capital Management LLC lifted its stake in Miragen Therapeutics by 5.3% in the fourth quarter. Geode Capital Management LLC now owns 230,127 shares of the medical research company’s stock worth $697,000 after purchasing an additional 11,541 shares during the last quarter. 47.45% of the stock is owned by institutional investors and hedge funds.

Miragen Therapeutics Company Profile

Miragen Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in discovering and developing proprietary RNA-targeted therapies with a specific focus on microRNAs and their role in diseases where there is a high unmet medical need. Its three lead product candidates include cobomarsen, an inhibitor of miR-155 for treating various blood cancers, such as cutaneous T-cell lymphoma, adult T-cell lymphoma/leukemia, diffuse large B-cell lymphoma, and chronic lymphocytic leukemia; Remlarsen, a replacement for miR-29, a microRNA that is found at abnormally low levels in various pathological fibrotic conditions, including cutaneous, ocular, and idiopathic pulmonary fibrosis; and MRG-110, an inhibitor of miR-92, a microRNA expressed in endothelial cells for the treatment of heart failure, as well as surgical incisions in high risk populations, severe lacerations, and severe burns in the United States and Japan.

Read More: What is a Lock-Up Period?

Get a free copy of the Zacks research report on Miragen Therapeutics (MGEN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Miragen Therapeutics (NASDAQ:MGEN)

Receive News & Ratings for Miragen Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Miragen Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.